Professor Fran Balkwill
Professor of Cancer Biology
My key area of interest is in cancer and the tumour microenvironment, especially in ovarian cancer. I study the links between cancer and inflammation and research ways of translating this to clinical trials.
Professor Ranjit Manchanda
Consultant Gynaecological Oncologist, Professor of Gynaecological Oncology
My main research focus is based on the development of population based approaches to genetic testing for risk stratification, cancer prevention and using targeted surgical approaches for cancer prevention in gynaecological cancers.
Dr Stéphanie Kermorgant
Reader in Cellular Oncology
We study the role of growth factor receptor signalling and intracellular trafficking (movement inside cells) in tumour growth and metastasis in the view of improving cancer therapy.
Dr Michelle Lockley
Reader in Medical Oncology, Honorary Consultant
Our lab aims to improve treatments for women with ovarian cancer, particularly those that are resistant to chemotherapy. We are interested in developing therapies that can adapt to the evolution of chemotherapy resistance over time.
Dr Oliver M. Pearce
Lecturer
The focus of our research is the tumour microenvironment and we are particularly interested in understanding the composition and function of the tumour extracellular matrix in immunosuppression. Cancer types we focus on include ovarian and breast cancers.
Dr Florian Laforets
My research in Prof Balkwill’s group focuses on imaging tumour-associated macrophages and other immune cells in live ex vivo tumour slices, in order to assess their behaviour and the impact of immunotherapies on the live tumour microenvironment.
Dr Jayeta Saxena
My research is focused on using a novel panel of chemo-resistant high grade serous ovarian cancer cells to discover new treatments that resensitise our cells to cis- and carboplatin.
Dr Nadeem Shaikh
We are using a variety of molecular and cytological techniques to study the mechanisms underlying chromosomal instability (CIN) in high grade serous ovarian cancer (HGSOC) that allow these highly adaptable tumours to become drug resistant.
Dr Vera Silva
I am trying to understand how new drugs in combination with carboplatin can help bypass therapy resistance in ovarian cancer.
Dr Naoka Taylor
High-grade serous ovarian cancer (HGSOC) represents the major subtype of ovarian cancer and displays high levels of chromosomal instability.
We are collaborating with the Balkwill and Lockley laboratories to investigate mechanisms driving chromosomal instability in gynaecological cancers.